USFDA grants priority review to Roche’s glofitamab
If approved, glofitamab would be the first fixed-duration CD20xCD3 T-cell engaging bi-specific antibody approved to treat the most…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
priority review
FDA grants priority review to Roche’s Lunsumio for Relapsed or Refractory Follicular Lymphoma
Approval is based on results from the pivotal phase-I/II clinical study of Lunsumio
US FDA to review full approval of Pfizer/BioNTech’s COVID-19 vaccine by January
The target action date does not mean the approval will not happen before January, the US Food and Drug Administration's Acting…